SUMMARY
Fibroblasts are major contributors to and regulators of inflammation and dominant producers of interleukin-6 (IL-6) in inflammatory diseases like rheumatoid arthritis. Yet, compared to leukocytes, the regulation of inflammatory pathways in fibroblasts is largely unknown. Here, we report that analyses of genes coordinately upregulated with IL-6 pointed to STAT4 and leukemia inhibitory factor (LIF) as potentially linked. Gene silencing revealed that STAT4 was required for IL-6 transcription. STAT4 was recruited to the IL-6 promoter after fibroblast activation, and LIF receptor (LIFR) and STAT4 formed a molecular complex that, together with JAK1 and TYK2 kinases, controlled STAT4 activation. Importantly, a positive feedback loop involving autocrine LIF, LIFR, and STAT4 drove sustained IL-6 transcription. Besides IL-6, this autorine loop also drove the production of other key inflammatory factors including IL-8, granulocyte-colony stimulating factor (G-CSF), IL-33, IL-11, IL-1a, and IL-1b. These findings define the transcriptional regulation of fibroblast-mediated inflammation as distinct from leukocytes.
INTRODUCTION
Fibroblasts function as stromal cells in peripheral tissues and as fibroblastic reticular cells (FRCs) in lymph nodes where they influence the recruitment, retention, and survival of leukocytes and the generation and termination of immune responses (Fletcher et al., 2010; Katakai et al., 2004; Link et al., 2007) . In chronic inflammation, fibroblasts are increasingly recognized as important contributors and regulators of inflammation through their production of inflammatory cytokines such as IL-6, chemokines such as CCL-2, IL-8, and arachidonate metabolites (Bernardo and Fibbe, 2013; Bottini and Firestein, 2013) . Of these factors, IL-6 is a pleiotropic cytokine that plays a major role in the response to injury and infection (Kishimoto, 2005) . Elevated expression of IL-6 has been implicated in diverse human diseases including inflammatory and autoimmune disorders such as rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus, Castleman's disease, Behcet's disease, and systemic juvenile idiopathic arthritis as well as in coronary artery and neurologic diseases and in neoplasms (Hong et al., 2007; Waldner and Neurath, 2014; Wolf et al., 2014) . Genetic studies have implicated IL-6 alleles in the predisposition to several autoimmune disorders (Fishman et al., 1998; Lee et al., 2012; Li et al., 2014; Villuendas et al., 2002) . In rheumatoid arthritis (RA) patients, the joint fluids and plasma contain high concentrations of IL-6 and synovial and serum amounts of IL-6 correlate with RA disease activity (Hirano et al., 1988; Houssiau et al., 1988; Madhok et al., 1993) . Blockade of IL-6 action by tocilizumab, a humanized anti-IL-6 receptor blocking monoclonal antibody, is an effective treatment for reducing both inflammation and joint destruction in RA and is being tested in a number of other inflammatory disorders (Tanaka et al., 2014) . Importantly, fibroblasts are a major source of IL-6 as well as other inflammatory cytokines (Guerne et al., 1989; Okamoto et al., 1997) .
In many pathological states, inflammatory cytokines like TNF, IL-1, IL-17, and IL-6 are part of the overall inflammatory milieu (McInnes and Schett, 2007) . All of these cytokines are potent stimulators of fibroblasts and combinations of inflammatory stimuli like TNF and IL-17 can dramatically activate fibroblasts (Zrioual et al., 2009) . Much has been learned about the activation and transcriptional regulation of inflammatory factor production in leukocytes, while the regulation of fibroblast production of IL-6 and other inflammatory mediators is poorly understood. To better understand the transcriptional basis for inflammatory factor production by fibroblasts as occurs in chronic inflammatory diseases, we initially focused on IL-6 production after synergistic activation by TNF and IL-17, cytokines typically present in inflammatory disorders (Agarwal et al., 2008; McInnes and Schett, 2007) . We designed a screen for differentially expressed genes in primary human fibroblasts to identify the genes and specifically the transcription factors that were induced after fibroblast activation and whose expression patterns correlated with that of IL6. Analysis of gene expression data showed a marked upregulation of STAT4, a member of the signal transducers and activators of transcription factor family not previously implicated in IL6 transcription. Importantly, STAT4 silencing reduced IL-6 expression after stimulation and STAT4 was recruited to the IL6 promoter. We found that STAT4 participated in a positive autocrine signaling circuit mediated through leukemia inhibitory factor (LIF)-LIF receptor (LIFR) that is important for sustained IL-6 transcription. LIFR and STAT4 formed a molecular complex that, together with JAK1 and TYK2 kinases, controlled STAT4 activation. We found that this LIFR-STAT4 signaling pathway was broadly relevant for the production of a set of other key inflammatory factors including IL-8, G-CSF, IL-33, IL-11, IL-1a, and IL-1b in fibroblasts and LIFR is selectively expressed in fibroblasts but not many leukocytes. Taken together, our results implicate the autocrine LIF-LIFR positive feedback loop and STAT4 as essential signaling components in the regulation of key inflammatory mediator production in human fibroblasts. These findings not only underscore how differently IL-6 and other chemokines and cytokines are regulated in mesenchymal compared to hematopoietic cell lineages, but also provide insights for understanding the basis for fibroblast activation and inflammatory factor production in health and diseases.
RESULTS

Human Fibroblasts Produce IL-6 in Response to Pro-inflammatory Cytokines
To examine directly the ability of fibroblasts to produce IL-6 in the synovium of inflammatory arthritis, we tested both mouse and human samples. We found that fibroblasts were the dominant source for the production of IL-6 compared to leukocytes in the arthritic joints of K/BxN mice, a useful animal model of inflammatory arthritis ( Figure S1D ; Kouskoff et al., 1996) . A substantial portion of IL-6 production in rheumatoid arthritis (RA) also was derived from fibroblasts relative to other leukocytes including B cells, T cells, and monocytes ( Figure S1B ). The higher proportional production of IL-6 by fibroblasts in the mouse model probably reflects the fact that mice were in the active phase of arthritis as opposed to human RA synovial samples obtained at the end stage of disease at the time of joint replacement surgery. To confirm this, we placed pieces of freshly isolated synovial tissue in media containing TNF and IL-17, the two cytokines commonly observed in active RA synovial fluids. After 48 hr, we isolated fibroblasts and monocytes, the two cell types that appear to have substantial contribution of IL-6 in the synovium. We observed that under these stimulated inflammatory conditions, fibroblasts produced markedly higher amount of IL6 mRNA while monocytes did not change their IL6 mRNA relative to that from the freshly isolated tissue (Figure S1C ). This suggests that in inflammatory environments such as those found in the active phase of RA, fibroblasts are a major source of IL-6.
To partially model the inflammatory milieu in RA, we examined the in vitro responses of primary cultured human fibroblasts, including those from synovial, skin, and lung tissues after stimulation with TNF or the combination of TNF and IL-17 (Noss et al., 2015; Zrioual et al., 2009 ). Fibroblasts responded dramatically to the combined stimulation of TNF and IL-17 compared to TNF or IL-17 alone by producing substantial amounts of IL-6 ( Figure 1A ) that were sustained even after 72 hr ( Figure 1B ). To examine IL-6 expression over time, we stimulated primary human fibroblast cell lines, OA-4 and RA-32, with TNF + IL-17 and collected supernatant media and RNA samples at various time points. We observed that increases in IL-6 protein ( Figure 1C ) after stimulation reflected similar increases in IL6 mRNA ( Figure 1D ). This suggests that a transcriptional and/or post-transcriptional mechanism is involved. Here, we focused on the transcriptional regulation of IL-6 in human fibroblasts.
STAT4 Is a Transcription Factor Regulating IL-6 Expression
To identify transcription factors involved in IL-6 expression, we used four primary human fibroblast cell lines, two derived from RA patients (RA-32, RA-449) and two from osteoarthritis (OA) patients (OA-6, OA-502), and stimulated them with TNF or the combination of TNF and IL-17 for approximately 20 hr before collecting RNA samples for genome-wide expression profiling. Because TNF and IL-17 combined stimulation resulted in an enhanced production of IL-6 compared to TNF alone ( Figures  1B and 1C) , we hypothesized that some transcription factors involved in IL-6 expression would likely have higher expression under the TNF + IL-17 combined stimulation. To identify such transcription factors, using genome-wide expression data, we calculated the fold induction for each gene by dividing its normalized expression after TNF or TNF + IL-17 with its expression in unstimulated samples. Genes whose expression after TNF + IL-17 stimulation were more than 2-fold higher than TNF alone, across all four fibroblasts lines, were selected for further study ( Figure 2A ). This group of genes includes four transcription factors (TFs), namely EHF, ELF3, CEBPD, and STAT4.
ELF3 and CEBPD TFs have previously been implicated in IL-6 expression in murine dendritic and osteoblastic cells (Kushwah et al., 2011; Ruddy et al., 2004) . However, STAT4 and EHF were not known to be directly involved in IL-6 gene expression. To determine whether ELF3, EHF, CEBPD, and STAT4 played a role in IL-6 regulation in human fibroblasts, we used siRNAs to silence their expression ( Figure 2B ). We observed that silencing of transcription factors known to regulate IL-6 such as NF-kB/p52, NF-kB/p65, C/EBPb, C/EBPd, and STAT3 all reduced IL-6 production, with p52, p65, and C/EBPb having the strongest effects. On the other hand, while silencing of ELF3, EHF, and STAT1 did not appear to alter IL-6 production, STAT4 silencing resulted in marked reduction of IL-6. STAT4 has not previously been implicated in IL-6 regulation, so we chose to focus on STAT4 for further study.
Consistent with the microarray data, we observed STAT4 protein upregulation after TNF and TNF + IL-17 stimulation, and combined stimulation resulted in even higher expression of STAT4 ( Figure 2C ). Of note, STAT4 siRNA was effective in silencing basal and induced expression of STAT4, but it did not affect STAT3 expression ( Figure 2C ). Importantly, silencing of STAT4 had a strong effect on IL-6 but not on matrix metalloprotease-3 (MMP3) expression ( Figure S2G ). We also observed that although silencing of NF-kB/p65 and C/EBPb did not affect basal STAT4 protein, they prevented STAT4 from being upregulated after stimulation ( Figure S3A ). This suggests that p65 and C/EBPb may be involved in the induction of STAT4.
To further confirm the role of STAT4 in IL-6 regulation, we transfected the siRNA against STAT4 into additional primary human fibroblast lines derived from synovial, skin, and lung tissues. We observed that STAT4 silencing not only affected IL-6 expression in synovial fibroblasts, it also led to a reduction in IL-6 production in primary human lung and skin fibroblasts ( Figure 2D ). In addition, when analyzing the ability of STAT4 to induce IL-6 expression in a time course experiment, we observed that fibroblasts expressing STAT4 siRNA were less efficient at inducing IL6 mRNA ( Figure 2E ) and consequently IL-6 protein ( Figure S3E ) than cells expressing a control siRNA. The effect was particularly more pronounced at later time points, which is not the case with other transcripts including CXCL5 and SLC7A2 (Figures S3C and S3D) . Furthermore, when examining IL-6 and STAT4 expression in fibroblasts freshly isolated from disaggregated human synovium, we also obtained results similar to those from cultured fibroblast lines, namely both IL-6 and STAT4 were upregulated after TNF + IL-17 combined stimulation (Figures 2F and 2G) . This suggests that STAT4 plays a central role in IL-6 regulation in fibroblasts.
To further study the role of STAT4, we created retrovirusbased overexpression vectors carrying wild-type STAT4 and a phospho mutant STAT4 in which the tyrosine 693 residue was changed to alanine to prevent STAT4 from being phosphorylated, rendering it inactive ( Figure 3A ). We used a primary human lung fibroblast line to generate cells stably expressing these constructs. Under basal conditions, no phosphorylation of STAT4 was detected. As expected, after TNF + IL-17 stimulation, only wild-type STAT4 was phosphorylated but not the mutant (Figures 3B and S4A) . To examine whether STAT4 can be directly recruited to the IL6 promoter, we performed chromatin immunoprecipitation using resins containing an anti-FLAG antibody Figure 1 . Expression of IL-6 by Human Fibroblasts (A) Primary cultured human fibroblasts derived from OA and RA synovium as well as skin and lung fibroblast lines were unstimulated (Basal) or stimulated with TNF (1 ng/mL) or TNF (1 ng/mL) + IL-17 (1 ng/mL) for approximately 20 hr, supernatants were collected, and IL-6 release measured by ELISA. (B) Sustained production of IL-6. RA-355 fibroblasts were treated with TNF (1 ng/mL) or TNF (1 ng/mL) + IL-17 (1 ng/mL) for 24, 48, and 72 hr, supernatants were collected, and IL-6 secretion measured by ELISA. (C and D) IL-6 protein and mRNA expression over time. OA-4 and RA-32 fibroblasts were stimulated with TNF (1 ng/mL) or TNF (1 ng/mL) + IL-17 (1 ng/mL) for various durations of time as indicated before RNA and supernatants were collected. IL-6 protein was measured by ELISA. The amount of IL6 mRNA was measured by qPCR and normalized to GAPDH. Fold induction was calculated by dividing the normalized IL6 mRNA at a certain time point with that at time 0 hr. Error bars represent SD of triplicate technical replicates. Data are representative of two independent experiments. See also Figure S1 . against the FLAG tag at the C terminus of the overexpressed STAT4. We observed that after TNF + IL-17 stimulation, only wild-type STAT4 was recruited to the IL6 promoter but not the phosphorylation mutant ( Figure 3C ). Moreover, since the IRF1 promoter is a known STAT4 binding target (Galon et al., 1999) and the IRF1 transcript is induced after TNF + IL-17 stimulation ( Figure S4D ), as a positive control, we also quantified the recruitment of STAT4 to this promoter ( Figure 3D ). Similar to the pattern observed at the IL6 promoter, only wild-type STAT4 was able to bind to the IRF1 promoter. In addition, when performing chromatin immunoprecipitation using an anti-STAT4 antibody against endogenous STAT4 from fibroblasts without STAT4 overexpression, we also observed increases in STAT4 recruitment to the IL6 and IRF1 promoters after stimulation (Figure S4B) . Moreover, of several promoter regions upstream of the IL6 transcription start site (TSS), the most proximal region lying within 500 bp of the TSS has the highest enrichment of STAT4 ChIP-DNA compared to other more distal regions (Figure S4C ). This suggests that STAT4 is directly involved in the transcriptional regulation of IL-6.
LIFR and gp130 Play an Important Role in IL-6 Regulation Activation of STAT transcription factors usually requires an upstream receptor where STATs bind (Schindler, 2002) . Traditionally, STAT4 is known to be regulated via the IL-12 and IL-23 cytokine receptors in leukocytes (Bacon et al., 1995; Cho et al., 1996) . However, the expression of these receptors across multiple fibroblast lines tested was very low ( Figure 4A ), implying that STAT4 is probably not regulated by the IL-12 and IL-23 receptor family in fibroblasts. Other receptors including IL6ST (gp130) and IFNAR have been implicated in STAT4 activation (Collison et al., 2012; Tyler et al., 2007) . We found that these two receptors as well as the leukemia inhibitory factor receptor (LIFR), an IL-6 family ligand binding and gp130 associated receptor, are substantially expressed in fibroblasts ( Figure 4A ). Thus, we asked whether IFNAR2, gp130, and LIFR play any role in IL-6 expression. We observed that silencing of gp130 or LIFR but not IFNAR2 reduced IL-6 production significantly (Figure 4B) , implying that gp130 and LIFR play an important role in IL-6 production in fibroblasts.
To further confirm the role of LIFR, we used two different anti-LIFR blocking antibodies, namely 1C7 and 12D3. The 1C7 monoclonal antibody (mAb) competes with the ligand binding domain of LIFR whereas the 12D3 mAb blocks the association of LIFR and gp130 (Pitard et al., 1997; Taupin et al., 2001 ). Both anti-LIFR blocking mAbs were able to reduce IL-6 production in a dose-dependent manner ( Figure 4C ). In addition, we observed that LIFR silencing by siRNA in additional synovium-and skin-derived fibroblast lines also resulted in marked reduction of IL-6 ( Figure 4D ).
Since these data suggest that gp130, LIFR, and STAT4 play a role in IL-6 regulation, we asked whether or not these proteins interact with one another. Using an antibody against LIFR in immunoprecipitation experiments, we were able to detect the presence of both gp130 and endogenous STAT4 in the LIFR pulldown fraction ( Figure 4E ). Similarly, using an antibody against gp130, we were also able to detect the presence of both LIFR and STAT4 in the gp130 pulldown fraction ( Figure S5D ). Moreover, we observed that while the total amount of gp130 decreases after stimulation, its amount in the LIFR pulldown fraction actually increases, suggesting that there is additional recruitment of gp130 to the LIFR-containing complex after stimulation. On the other hand, both the input amount of LIFR and the pulldown amount of STAT4 do not appear to change, implying that STAT4 binds to LIFR even under basal conditions. Taken together, these data suggest that gp130, LIFR, and STAT4 form a molecular complex and STAT4 probably interacts with LIFR directly.
Activation of STAT4 requires phosphorylation of the tyrosine 693 (Y693) residue. To explore the receptor and kinases involved, we examined whether STAT4 phosphorylation was altered by siRNA silencing of JAK1, JAK2, TYK2, and LIFR in fibroblasts after TNF + IL-17 stimulation. We found that silencing of JAK1, TYK2, or LIFR but not JAK2 reduced STAT4 phosphorylation, implying that LIFR together with JAK1 and TYK2 are its normalized expression after TNF or TNF + IL-17 with that in unstimulated samples. Genes whose expression after TNF + IL-17 stimulation were more than 2-fold higher than TNF alone, across all four cell lines, were selected. This includes four transcription factors, namely EHF, ELF3, CEBPD, and STAT4. The heatmap color used for each gene was based on the fold difference in its expression between TNF + IL-17 versus TNF stimulation alone. (B) RA-1357 fibroblasts expressing siRNA against various transcription factors were stimulated with TNF (0.1 ng/mL) + IL-17 (1 ng/mL) for approximately 20 hr, supernatants were collected, and IL-6 was measured by ELISA. Fraction remaining was calculated by dividing the amount of IL-6 release from cells expressing siRNA specific for a transcription factor with that from cells expressing a control (Ctrl) siRNA. Error bars represent SD of triplicate technical replicates. Data are representative of three independent experiments. p value was calculated using the Student's t test (***p < 0.001). (C) RA-1357 fibroblasts expressing control (Ctrl) and STAT4 siRNA were stimulated with TNF (0.1 ng/mL) or TNF (0.1 ng/mL) + IL-17 (1 ng/mL) for approximately 20 hr before whole cell lysates were collected. Western blotting was performed using an anti-STAT4 antibody with anti-b-actin as loading controls. Basal represents STAT4 protein expression under unstimulated conditions. (D) Role of STAT4 in IL-6 expression across a series of fibroblast types. Fibroblasts derived from synovium (OA, RA), skin, and lung tissues expressing STAT4 siRNA were stimulated with TNF (0.1 ng/mL) + IL-17 (1 ng/mL) for approximately 20 hr, supernatants were collected, and IL-6 was measured by ELISA. Fraction remaining was calculated as in (B). A control siRNA was used for each cell line and one representative control siRNA is shown. Error bars represent SD of triplicate technical replicates. Data are representative of two independent experiments. (E) Effect of STAT4 silencing on IL6 mRNA expression. RA-1357 fibroblasts expressing control (Ctrl) and STAT4 siRNA were stimulated with TNF (0.1 ng/mL) + IL-17 (1 ng/mL) for different amounts of time before RNA samples were collected. The amount of IL6 mRNA was measured by qPCR and normalized to GAPDH. Error bars represent SEM of biological duplicates. (F and G) IL-6 (F) and STAT4 (G) protein expression in freshly isolated human synovial fibroblasts rather than cultured cell lines. Synovial fibroblasts freshly disaggregated from human synovium were stimulated with TNF (1 ng/mL) + IL-17 (1 ng/mL) for 20 hr before supernatants (F) and whole cell lysates (G) were collected. IL-6 release was measured by ELISA and STAT4 by western blotting. Error bars represent SD of triplicate technical replicates. Western blotting was performed using an anti-STAT4 antibody with anti-alpha-tubulin as loading controls. Efficiency of siRNA silencing was assessed by western blotting and qPCR. See also Figures S2 and S3. involved in the phosphorylation of STAT4 ( Figure 4F ). To further confirm the role of LIFR in STAT4 phosphorylation, we used the 1C7 mAb that blocks the interaction between LIFR and its ligand. The presence of this mAb prevented STAT4 phosphorylation ( Figure S5F ). To further confirm the role of JAK1 and TYK2 on STAT4 function, we used several JAK inhibitors including filgotinib, tofacitinib, decernotinib, and ruxolitinib. We found that only the inhibitors that block both JAK1 and TYK2, namely filgotinib and decernotinib, displayed dose-dependent effects on IL-6 production; tofacitinib and ruxolitinib did not since they do not affect TYK2 ( Figure S5G) . Similarly, silencing of JAK1 or TYK2 individually had only partial effects on IL-6 production whereas silencing of both kinases together strongly suppressed IL-6 ( Figure S5H ).
Autocrine LIF Is Required for IL-6 Regulation LIFR has been shown to bind several IL-6 family ligands including cardiotrophin-1 (CTF-1), ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor (LIF) (Bauer et al., 2007) . Of these ligands, only LIF mRNA expression increased in a manner similar to that of IL6 mRNA after TNF or TNF + IL-17 combined stimulation of fibroblasts ( Figure 5A ). Increases in LIF mRNA after stimulation also could be detected at the protein level ( Figure 5B ). In addition, we observed that LIF expression increased rapidly as soon as 1 hr after fibroblast stimulation (Figures 5C and S6B) . Thus, we hypothesized that LIF may be a key ligand for LIFR. To determine whether LIF plays a role in IL-6 production, we used both siRNA and blocking antibody against LIF. Silencing LIF by siRNA or anti-LIF blocking antibody reduced Figure 3 . Recruitment of STAT4 to the IL6 Promoter (A) STAT4 overexpression constructs. Wild-type (WT) and a phosphorylation-defective (Y693A) STAT4 were cloned into a retroviral vector (pQCXIX, Clontech). A FLAG tag was inserted at the C terminus of STAT4 for affinity purification and western blotting. Retro viruses carrying these STAT4 constructs were made and used to transduce a human lung fibroblast line that stably expressed the construct after puromycin selection. (B) Lung fibroblast cell lines generated in (A) were stimulated with TNF (1 ng/mL) + IL-17 (1 ng/mL) for 0, 3, and 6 hr before whole cell lysates were collected. Western blots were performed using anti-pSTAT4-Y693 for phosphorylated STAT4 and anti-FLAG for total STAT4. (C and D) Recruitment of STAT4 to the IL6 (C) and IRF1 (D) promoter. Lung fibroblasts overexpressing wild-type (WT) or phospho-defective (Y693A) STAT4 protein were stimulated with TNF (1 ng/mL) + IL-17 (1 ng/mL) for 0 and 6 hr before cells were fixed with formaldehyde. Chromatin immunoprecipitation (ChIP) was carried out using a FLAG resin. The amount of DNA precipitated was quantified using qPCR. Fold recruitment was calculated by dividing the amount of ChIP DNA at 6 hr (normalized with input DNA) with that at 0 hr (normalized with input DNA). Error bars represent SEM of triplicate biological replicates. p value was calculated using the Student's t test (***p < 0.001). See also Figure S4 . (legend continued on next page) IL-6 production and using both the siRNA and antibody together was even more effective in blocking LIF and subsequent IL-6 expression ( Figure 5D ). This suggests that LIF produced by fibroblasts after TNF and IL-17 stimulation acts as an autocrine ligand via LIFR in the regulation of IL-6.
LIFR and STAT4 Are Involved in IL-6 Regulation under Various Inflammatory Conditions
Fibroblasts are versatile cells that can produce IL-6 in the context of various inflammatory conditions. We have shown that LIFR and STAT4 play an important role in IL-6 expression in fibroblasts after TNF + IL-17 stimulation. Next, we asked whether silencing of STAT4 or LIFR by siRNA also resulted in reduction of IL-6 release after fibroblast stimulation by IL-1b, TNF, or lipopolysaccharide (LPS) (Figures 6A-6C ) (all of these stimulations also led to increased LIF production [ Figure S6C] ). These results suggest that autocrine LIF, LIFR, and STAT4 form key components in IL-6 transcriptional regulation in fibroblasts under various inflammatory conditions.
LIFR and STAT4 Regulate Many Key Inflammatory Mediators and LIFR Is Selectively Expressed in Fibroblasts
After TNF + IL-17 stimulation of fibroblasts, besides IL-6, we also observed increases in the production of a series of inflammatory cytokines and chemokines including IL-8, G-CSF, IL-33, IL-11, IL-1a, and IL-1b. Importantly, in fibroblasts expressing a STAT4 or LIFR siRNA, the expression of all these inflammatory molecules, like IL-6, were markedly reduced ( Figures 6D-6I ). In addition, LIFR mRNA expression was detectable only in fibroblasts but not in leukocytes including B cells, T cells, and monocytes freshly isolated from the synovium of RA patients ( Figure 6K ). Taken together, these results define a critical and selective role for LIFR and STAT4 in the regulation of many key inflammatory mediators produced by fibroblasts under a variety of activation conditions.
DISCUSSION
Fibroblasts are well known for their physiological roles in matrix remodeling and wound healing. Over the past few years, their central roles in regulating and mediating inflammation in a variety of pathological conditions have become clear. In lymph nodes, fibroblasts organize the T cell zones and are called fibroblastic reticular cells (FRCs) . These fibroblasts produce chemokines and cytokines that retain and support the survival of T cells and dendritic cells to enable the initiation of potent immune responses (Fletcher et al., 2010) . After microbial antigens from peripheral tissues elicit immune responses, the FRCs in lymph nodes produce nitric oxide and surface inhibitory receptors that help dampen and terminate T cell responses (Fletcher et al., 2011) . In tumor tissues, fibroblasts referred to as stromal cells can profoundly inhibit anti-tumor immune responses that are reactivated upon removal of the inhibitory stromal cells (Kraman et al., 2010) . In contrast to these inhibitory examples, fibroblasts activated in peripheral tissues like the synovium in RA are key drivers of inflammation as the cytokines and chemokines produced by them have been shown to influence the function of macrophages, lymphocytes, and neutrophils (Donlin et al., 2014; Fox et al., 2010; Lally et al., 2005) .
Given the key role of IL-6 as a hallmark inflammatory cytokine made by fibroblasts and the relative lack of understanding of IL-6 regulation in mesenchymal cell types, we aimed to explore the transcriptional regulation of IL-6 in human fibroblasts. To model fibroblast activation by cytokines important in RA, we stimulated them with the combination of TNF and IL-17 which results in striking expression of IL-6. We employed global gene expression profiling data from four primary fibroblast lines derived from human synovium, hypothesizing that genes that are involved in IL-6 regulation might have expression patterns related to that of IL6 mRNA. Using this criterion, we identify four transcription factors, namely EHF, ELF3, CEBPD, and STAT4. We found that STAT4 silencing strongly affected IL-6 production in fibroblasts derived from multiple tissues including synovium, skin, and lung. By chromatin immunoprecipitation, we have shown that only wildtype STAT4, but not the phosphorylation-defective mutant, was recruited to the IL6 promoter after stimulation, suggesting that STAT4 is directly involved in IL-6 regulation in fibroblasts.
In addition, we found that blocking of LIFR by siRNA or mAb markedly reduced IL-6 production. Further, LIFR silencing affected IL-6 expression in several fibroblast lines derived from (B) RA-1357 fibroblasts expressing siRNA against various cell surface receptors were stimulated with TNF (0.1 ng/mL) + IL-17 (1 ng/mL) for approximately 20 hr, supernatants were collected, and IL-6 was measured by ELISA. Fraction remaining was calculated by dividing the amount of IL-6 released from cells expressing an siRNA against a receptor with that from cells expressing a control (Ctrl) siRNA. LIFR, #1 and LIFR, #2 represent two different siRNAs against the leukemia inhibitory factor receptor (LIFR). Error bars represent SD of triplicate technical replicates. Data are representative of three independent experiments. p value was calculated using the Student's t test (***p < 0.001). (C) Cell surface blocking of LIFR. RA-1357 fibroblasts were stimulated with TNF (0.1 ng/mL) + IL-17 (1 ng/mL) for approximately 20 hr in the presence of mouse monoclonal antibodies (mAb 1C7 and 12D3) targeting different domains of LIFR. Fraction remaining was calculated by dividing the amount of IL-6 released from cells under a blocking condition with that from cells treated with an isotype control antibody at the same concentration. Error bars represent SD of triplicate technical replicates. Data are representative of two independent experiments. (D) Role of LIFR across fibroblast types. Synovial and skin fibroblasts expressing a LIFR siRNA were stimulated with TNF (0.1 ng/mL) + IL-17 (1 ng/mL) for approximately 20 hr, supernatants were collected, and IL-6 release was measured by ELISA. Fraction remaining was calculated as in (B). A control (Ctrl) siRNA was used for each cell line and one representative control siRNA is shown. Error bars were calculated as in (C). (E) Endogenous interaction of LIFR with gp130 and STAT4. Cell lysates were collected from primary lung fibroblasts stimulated with TNF (1 ng/mL) + IL-17 (1 ng/mL) for 0, 6, and 15 hr. Immunoprecipitation was performed using an anti-LIFR or control antibody (Ctrl IgG). Antibodies against LIFR, STAT4, and gp130 were used to detect the presence of these proteins in the LIFR pulldown fraction. (F) Role of LIFR and JAK kinases in STAT4 phosphorylation. Lung fibroblasts overexpressing wild-type STAT4 were transfected with siRNA against JAK1, JAK2, TYK2, LIFR, or control (Ctrl) for 48 hr. Cells were then stimulated with TNF (1 ng/mL) + IL-17 (1 ng/mL) for 6 hr before whole cell lysates were collected. Detection of STAT4 phosphorylation was performed using an anti-pSTAT4-Y693 antibody. Total STAT4 was probed using an anti-FLAG antibody. Similar results were observed using synovial fibroblasts overexpressing wild-type STAT4 (data not shown). Efficiency of siRNA silencing was assessed by western blotting and qPCR. See also Figure S5 . skin or synovium. Of the possible LIFR ligands, only LIF is induced rapidly after stimulation of fibroblasts, and its expression exhibits a pattern similar to IL-6 and STAT4. Blocking LIF by either siRNA or blocking antibody was effective in reducing IL-6 production. To establish the physical and functional connection between STAT4, LIFR, and LIFR's co-receptor gp130, we performed immunoprecipitation and revealed that both endogenously expressed STAT4 and gp130 could be detected in the LIFR pulldown fraction. This suggests that STAT4, LIFR, and gp130 interact with one another. In human vascular smooth muscle and endothelial cells, STAT4 has been shown to be phosphorylated via activation of JAK1 and TYK2 (Dumler et al., 1998 (Dumler et al., , 1999 . Here in fibroblasts, we have shown that silencing of LIFR, JAK1, or TYK2 resulted in a reduction in STAT4 phosphorylation.
We found that silencing of STAT4 or LIFR resulted in reduction of IL-6 after stimulation by inflammatory factors besides TNF and IL-17, including IL-1b, TNF, and Toll-like receptor signaling. Moreover, besides IL-6, fibroblasts produced IL-8, G-CSF, IL-33, IL-11, IL-1a, and IL-1b after TNF and IL-17 stimulation, and the production of these cytokines and chemokines is markedly reduced when STAT4 or LIFR expression was silenced by siRNA. Together, (D) Effect of LIF blocking. LIF expression was blocked by using either an siRNA or antibody (IgG) against LIF. Antibody was added approximately 1 hr before cells were stimulated with TNF (0.1 ng/mL) + IL-17 (1 ng/mL) for about 20 hr and IL-6 release in the supernatants was measured by ELISA. Error bars were calculated as in (B). p value was calculated using the Student's t test (***p < 0.001). Efficiency of LIF silencing was assessed by ELISA. See also Figure S6 .
(legend on next page) these data suggest that LIF, LIFR, and STAT4 are important regulators not only of IL-6, but of a module of the major inflammatory mediators in inflammatory reactions involving fibroblasts.
Based on a number of human genetic studies, a common haplotype of the STAT4 gene locus has been shown to be associated with susceptibility to rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and primary Sjö gren's syndrome leading to suggestions that STAT4 is a pan autoimmune factor (Korman et al., 2008; Remmers et al., 2007) . In the case of RA, several single-nucleotide polymorphisms in the large third intron of STAT4 appear to be associated with the risk of developing the disease. Although a variant haplotype of STAT4 and possibly multiple polymorphisms found within it are important in predisposing toward RA and SLE, the questions of how and in which cell types STAT4 acts are not yet known. CD4 + T cells seem to be one likely cellular candidate as STAT4 is known to help promote these cells to differentiate into inflammatory subsets, T helper 1 (Th1) cells via IL-12R and T helper 17 (Th17) cells via IL-23R. However, our work on STAT4 as an important transcription factor for fibroblast-mediated inflammation together with previous studies that implicate the role of fibroblasts in RA (Bottini and Firestein, 2013; Lee et al., 2007; Lefevre et al., 2015) suggest that dysregulation of STAT4 in fibroblasts also may be an important contributor to the risk of disease or disease progression. LIF is a pleiotropic cytokine of the IL-6 family, and its concentrations in the synovial fluids of RA patients are elevated and correlate with the concentrations of IL-1, IL-8, and IL-6 (Enomoto et al., 2003) . In a murine model of arthritis, Lif-deficient mice were shown to have a reduction in clinical arthritis severity compared to wild-type disease controls (Upadhyay et al., 2012) . Although LIF has been reported to be produced by fibroblasts (Suman et al., 2013) , its autocrine role on IL-6 regulation after inflammatory stimulation was not previously known. In addition, other autocrine signaling involving IL-6-IL-6R and STAT3 circuit has been described for fibroblasts (Ogura et al., 2008) . However, IL-6, IL-6R, and STAT3 are also commonly expressed by some leukocytes. On the contrary, as LIFR appears to be selectively expressed in fibroblasts and not many leukocytes, this suggests that the autocrine signaling involving LIF, LIFR, and STAT4 is rather unique and may help explain the role of fibroblasts as key drivers in the sustained production of many inflammatory cytokines in RA and other diseases.
Fibroblasts and other mesenchymal cells play a crucial role in regulating and mediating inflammation in lymph nodes, tumors, and inflammatory autoimmune diseases. Here, we identify the autocrine LIF, LIFR, STAT4 circuit as a critical driver of IL-6 and a group of other inflammatory mediators that recruit or activate leukocytes and as well as other tissue cells. Our findings underscore how differently IL-6 and other inflammatory factors are regulated in mesenchymal cell lineages. In order to sustain transcription of inflammatory genes, a set of proteins not previously known to work together form the essential components of a cellautonomous signaling pathway. Defining stromal cell biology will be important to identify relevant therapeutic targets as well as to understand how drugs may act differently on stromal cells compared to leukocytes.
EXPERIMENTAL PROCEDURES Cell Lines and Reagents
Human synovial fibroblasts were isolated as previously described (Kiener et al., 2006 ) from tissues discarded after synovectomy or joint replacement surgery. Each line was derived from a unique donor and used experimentally between passages 5 and 8. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gemini), 2 mM L-glutamine, 50 mM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids (Life Technologies). Human skin and lung fibroblasts were purchased from Lonza and cultured using the same media. Freshly isolated synovial fibroblasts, T cells, B cells, and monocytes were prepared by digesting pieces of tissues with 4 mg/mL collagenase type 4 (Worthington), 0.8 mg/mL DispaseII (Roche), and 0.2 mg/mL DNase I (Roche) in DMEM at 37 C for 1 hr, followed by sorting cells enriched for and anti-FLAG resins (Sigma). All siRNAs (Silencer Select) were purchased from Life Technologies. All JAK inhibitors were purchased from SelleckChem. qPCR and ChIP primers were purchased from Integrated DNA Technologies and their sequences are listed in Table S1 . All human sample research was approved by the Brigham and Women's Hospital Institutional Review Board.
Gene Expression Profiling
Fibroblasts (RA-32, RA-449, OA-6, OA-502) were plated on day 1 at 50,000 cells per well in 24-well plates in 10% FBS-containing media. Cells were serum Figure S1A ) and each number denotes a different donor. The amount of LIFR mRNA was measured by qPCR using GAPDH as the normalization control. Error bars represent SD of triplicate technical replicates. Note that LIFR mRNA could not be detected in T cells, B cells, and monocytes. See also Figure S6 . starved on day 2 by changing to 1% FBS-containing media. Cells were either left unstimulated or stimulated with TNF (1 ng/mL) or TNF (1 ng/mL) + IL-17 (1 ng/mL) for approximately 20 hr on day 3 before samples were collected in TRizol reagent (Life Technologies) and RNA was extracted using the RNeasy Mini Kit (QIAGEN). Expression profiling was performed using the Affymetrix HG U133 Plus version 2 arrays. Expression values were normalized using the Robust Multi-array Average (RMA) method. The microarray data used in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) .
Statistical Analysis
Error bars displayed throughout the manuscript represent standard deviation (SD) or standard error of the mean (SEM) and were calculated from triplicate technical or triplicate biological replicates as described in figure legends. Data shown are representative of two to three independent experiments including blots and gels. Statistical significance was determined using unpaired Student's t tests; ***p < 0.001. For multiple testing, Bonferroni correction was applied.
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